Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma

Taal, 2004, Epidemiology, of neuroendocrine tumors. Neuroendocrinology, 80, 3, 10.1159/000080731 Barakat, 2004, Neuroendocrine tumors, Endocr Related Cancer, 11, 1, 10.1677/erc.0.0110001 Madeira, 1998, Prognostic factors in patients with endocrine tumors of the duodenopancreatic area, Gut, 43, 422, 10.1136/gut.43.3.422 Pape, 2004, Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center, Ann N Y Acad Sci, 1014, 222, 10.1196/annals.1294.025 Panzuto, 2005, Prognostic factors and survival in endocrine tumor patients: comparison between gastro-intestinal and pancreatic localization, Endocr Related Cancer, 12, 1083, 10.1677/erc.1.01017 Corleto, 2004, Somatostatin receptors subtypes: basic pharmacology and tissue distribution, Digest Liver Dis, 36, S8, 10.1016/j.dld.2003.11.008 Oberg, 2004, Consensus on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system, Ann Oncol, 15, 966, 10.1093/annonc/mdh216 Plockinger, 2004, Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS), Neuroendocrinology, 80, 394, 10.1159/000085237 Garland, 2003, Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience, Aliment Pharmacol Ther, 17, 437, 10.1046/j.1365-2036.2003.01420.x Wymenga, 1999, Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms, J Clin Oncol, 17, 1111, 10.1200/JCO.1999.17.4.1111 Kaltsas, 2004, The diagnosis and management of advanced neuroendocrine tumors, Endocrine Rev, 25, 458, 10.1210/er.2003-0014 Aparicio, 2001, Antitumor activity of somatostatin analogues in progressive metastatic neuroendocrine tumors, Eur J Cancer, 37, 1014, 10.1016/S0959-8049(01)00073-9 Arnold, 1996, Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumors, Gut, 38, 430, 10.1136/gut.38.3.430 Shojamanesh, 2002, Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma, Cancer, 94, 331, 10.1002/cncr.10195 Solcia E, 2000, Klöppel G, Sobin LH (in collaboration with 9 pathologists from 4 countries). Histological Typing of Endocrine Tumors, 1 Panzuto, 2003, Staging of digestive endocrine tumors using helical computer tomography and somatostatin receptor scintigraphy, Ann Oncol, 14, 586, 10.1093/annonc/mdg160 Panzuto, 2004, Utility of combined use of plasma levels of chromogranin A and pancreatic polipeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors, J Endocrinol Invest, 27, 6, 10.1007/BF03350903 Janson, 1997, Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center, Ann Oncol, 8, 685, 10.1023/A:1008215730767 Arnold, 2005, Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial, Clin Gastroenterol Hepatol, 3, 761, 10.1016/S1542-3565(05)00481-7 Bajetta, 2005, Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?, Ann Oncol, 16, 1374, 10.1093/annonc/mdi258 Faiss, 2003, J Clin Oncol, 21, 2689, 10.1200/JCO.2003.12.142 Ricci, 2000, Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide, Ann Oncol, 11, 1127, 10.1023/A:1008383132024 Ducreux, 2000, The antitumoral effect of the long-acting analog Lanreotide in neuroendocrine tumors, Am J Gastroenterol, 95, 3276, 10.1111/j.1572-0241.2000.03210.x Rindi, 2003, Highlights on biology of endocrine tumors of the gut and pancreas, Endocr Related Cancer, 10, 427, 10.1677/erc.0.0100427